Jasper Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Jasper Therapeutics, Inc. carries a market capitalization of 208,033.00, placing it among publicly traded companies globally. Its enterprise value stands at -13.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 208,033.00 |
| Enterprise Value | -13.39M |
Share Statistics
Jasper Therapeutics, Inc. currently has 28.00M shares outstanding.
| Shares Outstanding | 28.00M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Jasper Therapeutics, Inc. maintains a current ratio of 2.26, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.26 |
| Quick Ratio | 1.57 |
| Debt / Equity | 22.26 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -141.49 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Jasper Therapeutics, Inc.'s stock has declined approximately -87.2% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.06.
| Beta (5Y) | N/A |
| 52-Week Price Change | -87.2% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.06 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -72.23M, while operating income came in at -73.03M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -73.03M |
| Pretax Income | -55.73M |
| Net Income | -55.73M |
| EBITDA | -72.23M |
| EBIT | -73.03M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Jasper Therapeutics, Inc. holds 14.14M in cash and equivalents against 757,000.00 in total debt, resulting in a net debt position of -14.14M. Total book value stands at -317.84M, with working capital of 11.30M providing operational flexibility.
| Cash & Cash Equivalents | 14.14M |
| Total Debt | 757,000.00 |
| Net Debt | -14.14M |
| Equity (Book Value) | -317.84M |
| Book Value Per Share | N/A |
| Working Capital | 11.30M |
Cash Flow
Jasper Therapeutics, Inc. produced -68.87M in operating cash flow over the past twelve months.
| Operating Cash Flow | -68.87M |
| Capital Expenditures | -7,000.00 |
| Free Cash Flow | -68.87M |
| FCF Per Share | N/A |
Scores
Jasper Therapeutics, Inc. posts an Altman Z-Score of -31.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -31.74 |